Novavax Share Price

Novavax Share Price

NASDAQ: NVAX | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • Similar Stocks
  • FAQs

Novavax Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

Novavax Share Price Chart

Line chart of the Novavax price trend over the selected period. The price rose overall, ranging from 7.86 to 8.29, ending at 7.95.
$0.00$0.00
L
Show Current Price
H

Novavax Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.46
Revenue (TTM)
$1.12T
Return On Equity (TTM)
35.38%
Profit Margin
39.19%
Debt to Equity
-1.36
Quarterly Earnings Growth YoY
-279.01%

Novavax Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$147.14$139.51$56.70$68.30
Net Profit$17.53-$9.49-$53.39-$31.38
Net Profit Margin11.91%-6.80%-94.16%-45.94%
Income ChangeN/A-154.14%-462.59%41.22%

Novavax Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$1981.87$983.71$682.16$1123.48
Net Profit-$657.94-$545.06-$187.50$440.30
Net Profit Margin-33.20%-55.41%-27.49%39.19%
Income ChangeN/A17.16%65.60%334.83%

Novavax Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets198.24431.48653.6555.29
Current Assets978.281128.941143.891703.39
Total Assets1176.511560.421797.492258.68
Non Current Liabilities892.181029.84879.28432.81
Current Liabilities412.081154.421635.142459.94
Total Liabilities1304.272184.262514.422892.76
Shareholders' Equity-127.75-623.84-716.93-634.08

Novavax Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-244.64-87.26-713.97-415.94
Investing-78.27-204.04-58.81-92.99
Financing27.74260.584.47324.99

Corporate Actions

Split
Ex-date: 10 May 2019

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Novavax Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

Novavax Share Price FAQs